Partnership Opportunities
Take the Spotlight in 2025
Your Global Platform to Foster New & Existing Relationships within the Rapidly Expanding Renal Field
With billion-dollar acquisitions, breakthrough therapies, and accelerated regulatory pathways reshaping the kidney disease landscape, the CKD field is in a transformative era. As drug developers prioritize their renal pipelines, opportunities abound—but so do the challenges. From optimizing biomarkers to improving clinical trial design and addressing unmet patient needs, innovation requires collaboration.
The 7th CKD Summit is your chance to position your brand in front of key decision-makers driving the future of renal drug development. Showcase your solutions to the leaders tackling the most complex R&D hurdles and capitalize on this unparalleled opportunity to establish your company as a trusted partner in advancing CKD care.
Download the event guide to explore how partnering with us can align your expertise with the leaders shaping the next wave of kidney disease innovation.
Why Partner?
CRO with Specialized Expertise in Design and Execution of Clinical Trials from Across Rare & Common Kidney Disorders
Non-Invasive Biomarkers for Earlier Diagnosis, Patient Stratification, & Monitoring of Renal Diseases
Advanced Imaging & Monitoring Technologies to Precisely Monitor Changes in Renal Function
Preclinical Models with Proven Translatability to Accurately Predict Human Renal Outcomes and Support Early-Stage Drug Development
Drug Discovery CROs Specializing in Uncovering Novel Targets for Renal Diseases and Advancing Early-Stage Drug Development
End-to-End Partner for Kidney Drug Development, Supporting All Phases from Discovery to Commercialization
or … Are You a Drug Developer Looking to Strengthen Your Position in the Renal Space?
Our 2025 Partners
Regeneron, Eli Lilly, Novo Nordisk, Novartis, GSK and AstraZeneca are amongst our other 200+ attendees that are seeking partners to help them in the following areas:
Contract Research – accelerate and support preclinical and clinical R&D and position yourself as the leading CRO in rare and common kidney disorders
Non-Invasive Biomarkers – communicate your capabilities to enhance the development and validation of fluid and imaging biomarkers to detect CKD at an earlier stage and more precisely monitor renal function
Preclinical Models – showcase your expertise in developing translatable, validated in vivo or in vitro models that reliably predict how drugs interact within human kidney tissue
Become a Partner
Ellie Bilko
Partnership Director
Hanson Wade
sponsor@hansonwade.com